Toshikazu Ban

Toyama Chemical Co., Ltd. develops and supplies pharmaceutical products. It engages in information collection, clinical development of pharmaceuticals and distribution of healthcare products. The company was founded on November 15, 1936 and is headquartered in Tokyo, Japan.

Part of FUJIFILM Holdings Corp., FUJIFILM Toyama Chemical Co. Ltd. brings innovative solutions to various industries such as healthcare, graphic systems, and digital imaging. The private company is based in Tokyo, Japan. The Japanese company's core technologies include chemical, mechanical, optical, electronic, and imaging technologies. With revenues of $21 billion in 2020, the company is committed to responsible environmental stewardship and good corporate citizenship. The company was founded in 1968, and the CEO is Misao Tsuda. FUJIFILM Toyama Chemical Co. was acquired by FUJIFILM Holdings Corp. from Daiichi Sankyo Co., Ltd. on October 01, 2006.

FUJIFILM Corp. engages in the provision of imaging and information solutions. Its offers photography equipment, supplies and services, optical devices, healthcare, high-performance materials, graphic systems, recording media, and industrial products. The company was founded on October 2, 2006 and is headquartered in Tokyo, Japan.

Cellular Dynamics International Japan Co., Ltd. manufactures biological products. The private company is based in Tokyo, Japan.

Part of FUJIFILM Holdings Corp., Fujifilm Pharma Co., Ltd. is a Japanese company that manufactures and distributes generic drugs and distributes long-term product listings.

Century Therapeutics, Inc. operates as a biotechnology company. It develops transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. The company has created a allogeneic cell therapy platform that includes induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from iPSCs, or iPSC-derived cells, clustered regularly interspaced short palindromic repeats, or CRISPR, mediated precision gene editing that allows it to incorporate multiple transgenes and remove target genes intended to optimize cell product performance, sophisticated protein engineering capabilities to develop proprietary next generation chimeric antigen receptors, or CARs, its proprietary Allo-EvasionTM technology intended to prevent rejection of its cell products by the host immune system, and cutting edge manufacturing capabilities intended to minimize product development and supply risk. Century Therapeutics was founded on March 5th, 2018 and is headquartered by Philadelphia, PA.